Effect of sustained measurable residue disease negativity and post‐remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults
Cancer Medicine · 2024-05 · 13 (10)
DOI: 10.1002/cam4.7310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.05.2024. Verfasst von Jiechen Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Neoplasm, Residual, Antineoplastic Combined Chemotherapy Protocols, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Plan of GH145-13 GuHai.
Abstract (Originalsprache)
Background
To explore the effects of monitoring measurable residual disease and post‐remission treatment selection on the clinical outcomes of B‐cell acute lymphoblastic leukemia (B‐ALL) in adults.
Methods
Between September 2010 and January 2022, adult patients with B‐ALL who received combination chemotherapy, with or without allogeneic hematopoietic stem cell transplantation (allo‐HSCT), were included in the retrospective study, which was approved by the Ethics Committee and the observation of Declaration of Helsinki conditions.
Results
One hundred and forty‐three B‐ALL patients achieved complete remission (CR) were included in the study, of whom 94 patients (65.7%) received allo‐HSCT in first complete remission (CR1). Multivariate analysis showed that the most powerful factors affecting OS were transplantation (hazard ratio [HR] = 0.540, p = 0.037) and sustained measurable residue disease (MRD) negativity (HR = 0.508, p = 0.037). The subgroup analysis showed that the prognosis of the allo‐HSCT group was better than that of the chemotherapy group, regardless of whether MRD was negative or positive after two courses of consolidation therapy. After consolidation therapy, the prognosis of patients with positive MRD remained significantly better in the allo‐HSCT group than in the chemotherapy group. However, no significant difference was observed in the prognosis between the allo‐HSCT and chemotherapy groups with negative MRD after consolidation therapy.
Conclusions
B‐ALL patients who achieve sustained MRD negativity during consolidation therapy have excellent long‐term outcomes even without allo‐HSCT. Allo‐HSCT is associated with a significant benefit in terms of OS and DFS for patients who were with positive MRD during consolidation therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
ORCID-Profile: Jianmin Yang
Förderung
- Plan of GH145-13 GuHai
Zitieren
APA
Yu, J., Luo, Y., Wang, L., Wang, T., Ye, M., Chen, J., Ni, X., Chen, L., Gao, L., & Yang, J. (2024). Effect of sustained measurable residue disease negativity and post‐remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults. Cancer Medicine, 13(10). https://doi.org/10.1002/cam4.7310
Vancouver
Yu J, Luo Y, Wang L, Wang T, Ye M, Chen J, et al. Effect of sustained measurable residue disease negativity and post‐remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults. Cancer Medicine. 2024;13(10). doi:10.1002/cam4.7310
BibTeX
@article{Yu2024,
author = {Yu, Jiechen and Luo, Yanrong and Wang, Libing and Wang, Tao and Ye, Mingyu and Chen, Jie and Ni, Xiong and Chen, Li and Gao, Lei and Yang, Jianmin},
title = {Effect of sustained measurable residue disease negativity and post‐remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {10},
doi = {10.1002/cam4.7310}
}
EUVIMED